CN110869354A - 脂肪酸衍生物及其用途 - Google Patents

脂肪酸衍生物及其用途 Download PDF

Info

Publication number
CN110869354A
CN110869354A CN201880045287.6A CN201880045287A CN110869354A CN 110869354 A CN110869354 A CN 110869354A CN 201880045287 A CN201880045287 A CN 201880045287A CN 110869354 A CN110869354 A CN 110869354A
Authority
CN
China
Prior art keywords
compound
substituted
hydrogen
hydroxy
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880045287.6A
Other languages
English (en)
Chinese (zh)
Inventor
G·凯斯
C·拉姆斯登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CN110869354A publication Critical patent/CN110869354A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C07C33/025—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond
    • C07C33/03—Acyclic alcohols with carbon-to-carbon double bonds with only one double bond in beta-position, e.g. allyl alcohol, methallyl alcohol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
    • C07D303/42—Acyclic compounds having a chain of seven or more carbon atoms, e.g. epoxidised fats
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880045287.6A 2017-07-07 2018-07-06 脂肪酸衍生物及其用途 Pending CN110869354A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529846P 2017-07-07 2017-07-07
US62/529,846 2017-07-07
PCT/US2018/041086 WO2019010414A1 (en) 2017-07-07 2018-07-06 FATTY ACID DERIVATIVES AND USE THEREOF

Publications (1)

Publication Number Publication Date
CN110869354A true CN110869354A (zh) 2020-03-06

Family

ID=63036390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880045287.6A Pending CN110869354A (zh) 2017-07-07 2018-07-06 脂肪酸衍生物及其用途

Country Status (9)

Country Link
US (2) US11555021B2 (enExample)
EP (1) EP3649115B1 (enExample)
JP (1) JP7234151B2 (enExample)
KR (1) KR102725883B1 (enExample)
CN (1) CN110869354A (enExample)
AU (1) AU2018297192B2 (enExample)
CA (1) CA3064132C (enExample)
MX (1) MX391168B (enExample)
WO (1) WO2019010414A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113121475A (zh) * 2021-03-30 2021-07-16 香港科技大学深圳研究院 不饱和脂肪酸类化合物及其制备方法和应用
CN113620923A (zh) * 2021-07-16 2021-11-09 扬州工业职业技术学院 一种低温电解液添加剂的制备方法及应用
CN115073295A (zh) * 2022-07-21 2022-09-20 山东大学 马齿苋中不饱和脂肪酸及其提取分离方法和应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
WO2024237316A1 (ja) * 2023-05-16 2024-11-21 国立大学法人東京大学 エポキシ化不飽和脂肪酸の皮膚線維化改善作用
EP4613730A1 (en) * 2024-03-05 2025-09-10 Centre National de la Recherche Scientifique Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022848A1 (en) * 1993-03-29 1994-10-13 Pace Asciak Cecil R Hepoxilin analogs useful as anti-inflammatory agents
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
WO2006106438A2 (en) * 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055613A (en) * 1988-02-18 1991-10-08 G. D. Searle & Co. Metabolites of pentanedioic acid derivatives
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
BR0012447A (pt) * 1999-07-15 2002-04-02 Lilly Co Eli Análogos de pseudomicina de cadeia lateral de n-acila
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7335689B2 (en) 2003-01-23 2008-02-26 Esperion Therapeutics, Inc. Dihydroxyl compounds and compositions for cholesterol management and related uses
DE102004037118A1 (de) 2004-07-30 2006-03-23 Degussa Ag Titandioxid enthaltende Dispersion
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
JP5552121B2 (ja) * 2008-09-04 2014-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
WO2013157926A1 (en) 2012-04-19 2013-10-24 Nyken Holding B.V. Geranyl geranyl acetone analogs and uses thereof
JP6160375B2 (ja) 2013-09-06 2017-07-12 ブラザー工業株式会社 画像記録装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022848A1 (en) * 1993-03-29 1994-10-13 Pace Asciak Cecil R Hepoxilin analogs useful as anti-inflammatory agents
US5616607A (en) * 1993-03-29 1997-04-01 Hsc Research And Development Limited Partnership Hepoxilin analogs
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
WO2006106438A2 (en) * 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIETER SPITELLER 等: "Oxidation of Linoleic Acid in Low-Density Lipoprotein: An Important Event in Atherogenesis", 《ANGEW. CHEM. INT. ED.》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113121475A (zh) * 2021-03-30 2021-07-16 香港科技大学深圳研究院 不饱和脂肪酸类化合物及其制备方法和应用
CN113620923A (zh) * 2021-07-16 2021-11-09 扬州工业职业技术学院 一种低温电解液添加剂的制备方法及应用
CN113620923B (zh) * 2021-07-16 2023-03-14 扬州工业职业技术学院 一种低温电解液添加剂的制备方法及应用
CN115073295A (zh) * 2022-07-21 2022-09-20 山东大学 马齿苋中不饱和脂肪酸及其提取分离方法和应用
CN115073295B (zh) * 2022-07-21 2023-12-26 山东大学 马齿苋中不饱和脂肪酸及其提取分离方法和应用

Also Published As

Publication number Publication date
EP3649115B1 (en) 2024-09-04
KR102725883B1 (ko) 2024-11-01
EP3649115A1 (en) 2020-05-13
AU2018297192B2 (en) 2022-02-17
US20220274940A1 (en) 2022-09-01
JP7234151B2 (ja) 2023-03-07
AU2018297192A1 (en) 2019-12-19
US20210139440A1 (en) 2021-05-13
MX391168B (es) 2025-03-21
WO2019010414A1 (en) 2019-01-10
CA3064132C (en) 2024-06-04
US12479812B2 (en) 2025-11-25
JP2020526505A (ja) 2020-08-31
KR20200027545A (ko) 2020-03-12
CA3064132A1 (en) 2019-01-10
EP3649115C0 (en) 2024-09-04
US11555021B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
US12479812B2 (en) Fatty acid derivatives and their use
Levy Resolvins and protectins: natural pharmacophores for resolution biology
Aursnes et al. Total synthesis of the lipid mediator PD1n-3 DPA: configurational assignments and anti-inflammatory and pro-resolving actions
Hansen et al. Protectins: Their biosynthesis, metabolism and structure-functions
Batsika et al. Saturated oxo fatty acids (SOFAs): A previously unrecognized class of endogenous bioactive lipids exhibiting a cell growth inhibitory activity
CN108472267B (zh) 用于抑制三甲胺产生的化合物和方法
Oliaro‐Bosso et al. Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol
EP2200564B1 (en) Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase
JP2019142887A (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
Wang et al. Structural identification of monounsaturated branched chain fatty acid methyl esters by combination of electron ionization and covalent adduct chemical ionization tandem mass spectrometry
Nesman et al. A new synthetic protectin D1 analog 3-oxa-PD1n-3 DPA reduces neuropathic pain and chronic itch in mice
JP2021525803A (ja) カンナビノイド及びそれらの使用
CN108026142A (zh) 孤儿核受体Nur77 的配体及其用途
Sim et al. Cinnamamides, novel liver X receptor antagonists that inhibit ligand-induced lipogenesis and fatty liver
Gong et al. Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice
Tungen et al. The first total synthesis of the lipid mediator PD2n-3 DPA
CN104080466B (zh) 阻碍蛋白质酪氨酸磷酸酶1b的二萜呋喃类化合物及其用途
Stepniewski et al. Synthesis, molecular modelling studies and biological evaluation of new oxoeicosanoid receptor 1 agonists
Straß et al. Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo
KR20080069177A (ko) 신규한 불포화 지방 하이드록시산 유도체 및 이의피부화장품학적 용도
WO2020245291A1 (en) Pyrrole derivatives as acc inhibitors
Ervik et al. Synthesis of the methyl ester of 17 (R/S)-Me-RvD5n-3 DPA and relief of postoperative pain in male mice
EP4559461A1 (en) Dual nlrp1 and nlrp3 inhibitors for use as a medicament
Arai et al. Design and synthesis of cyclopropane congeners of resolvin E3, an endogenous pro-resolving lipid mediator, as its stable equivalents
NIU et al. Enhancing bioactivities and chemical properties of A marine briarane-type diterpenoid with late-stage diversification

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination